Scarica l'app Stockscreener
1.63
3.16%
0.05
Precedente Chiudi:
$1.58
Aprire:
$1.59
Volume 24 ore:
428.27K
Relative Volume:
0.29
Capitalizzazione di mercato:
$51.43M
Reddito:
-
Utile/perdita netta:
$-69.00M
Rapporto P/E:
-0.5863
EPS:
-2.78
Flusso di cassa netto:
$-55.26M
1 W Prestazione:
-2.40%
1M Prestazione:
-4.12%
6M Prestazione:
+24.43%
1 anno Prestazione:
-69.59%
Intervallo 1D:
$1.59
$1.71
Intervallo di 1 settimana:
$1.46
$1.71
Portata 52W:
$1.05
$6.08
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.63 | 49.86M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | Piper Sandler | Overweight |
| 2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-12-15 | Ripresa | Jefferies | Buy |
| 2023-10-05 | Iniziato | Maxim Group | Buy |
| 2023-06-02 | Iniziato | Oppenheimer | Outperform |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-04-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-12-12 | Iniziato | Jefferies | Buy |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Reviewing Acrivon Therapeutics (NASDAQ:ACRV) & Innate Pharma (OTCMKTS:IPHYF) - Defense World
Why Acrivon Therapeutics Inc. stock is a value investor pickWeekly Risk Summary & AI Powered Buy/Sell Recommendations - mfd.ru
Trade Recap: Is Acrivon Therapeutics Inc showing insider buying2025 Sector Review & Smart Swing Trading Alerts - baoquankhu1.vn
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Drop in Short Interest - MarketBeat
Is Acrivon Therapeutics Inc. showing insider buying2025 Major Catalysts & Smart Investment Allocation Tips - mfd.ru
ACRV News Today | Why did Acrivon Therapeutics stock go up today? - MarketBeat
Short Squeeze: Why is Ameriprise Financial Inc stock going upJuly 2025 Rallies & Weekly High Momentum Picks - baoquankhu1.vn
Winners Losers: Will Acrivon Therapeutics Inc benefit from green energy policiesShare Buyback & Consistent Return Investment Signals - baoquankhu1.vn
Activity Recap: Is Acrivon Therapeutics Inc a good ESG investmentQuarterly Earnings Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $11.67 - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Large Increase in Short Interest - MarketBeat
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
RSI Check: Is Morgan Stanley Preferred Security a stock for growth or value investors2025 Fundamental Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
Sectors Review: What chart patterns are forming on Acrivon Therapeutics IncTrade Entry Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - Bolsamania
CEO Change: Does Vinci Partners Investments Ltd stock benefit from AI growthMarket Volume Report & Advanced Technical Signal Analysis - baoquankhu1.vn
Acrivon to present ACR-368 endometrial cancer data at ESGO congress - Investing.com Nigeria
Dow Update: Can Acrivon Therapeutics Inc beat the S P 5002025 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn
Endometrial cancer trial ACR-368 to be featured at European oncology event - Stock Titan
Acrivon Therapeutics Announces Late-Breaking Oral - GlobeNewswire
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), RegenXBio (RGNX) and Nurix Therapeutics (NRIX) - The Globe and Mail
Penny Stocks To Watch In January 2026 - Yahoo Finance
Insider Spends US$82k Buying More Shares In Acrivon Therapeutics - simplywall.st
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares - Yahoo Finance
Tech Rally: Can Acrivon Therapeutics Inc beat the S P 500Earnings Recap Report & Technical Buy Zone Confirmations - baoquankhu1.vn
Price Action: Can Acrivon Therapeutics Inc ride the EV waveDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Acrivon Therapeutics CEO Blume-Jensen buys $82k in shares By Investing.com - Investing.com South Africa
Acrivon Therapeutics CEO Blume-Jensen buys $82k in shares - Investing.com
Top Brass Doubles Down on Acrivon With Bold Insider Buying Spree - TipRanks
Volume Report: Is BMLPRJs ROE strong enoughEarnings Risk Report & Risk Managed Investment Signals - baoquankhu1.vn
Insider Buying: Adam Levy Acquires Shares of Acrivon Therapeutics Inc (ACRV) - GuruFocus
Acrivon Therapeutics (NASDAQ:ACRV) CFO Adam Levy Acquires 8,832 Shares - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) CEO Peter Blume-Jensen Purchases 49,000 Shares - MarketBeat
Aug Decliners: Can Acrivon Therapeutics Inc ride the EV waveCEO Change & Smart Allocation Stock Tips - baoquankhu1.vn
Top Acrivon Executive Makes Bold Insider Move That Signals Growing Confidence - TipRanks
Acrivon Therapeutics COO Devroe buys $17k in shares By Investing.com - Investing.com Nigeria
Insider Buying: Eric Devroe Acquires 10,000 Shares of Acrivon Th - GuruFocus
Acrivon Therapeutics COO Devroe buys $17k in shares - Investing.com
Acrivon Therapeutics (NASDAQ:ACRV) COO Purchases $17,200.00 in Stock - MarketBeat
U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction - Intellectia AI
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush - The Globe and Mail
Movement Recap: What risks investors should watch in Acrivon Therapeutics Inc stockMarket Performance Summary & Safe Entry Momentum Stock Tips - Bộ Nội Vụ
Acrivon Therapeutics Inc. (ACRV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Growth Value: Can Acrivon Therapeutics Inc expand into new marketsJuly 2025 Momentum & Entry Point Confirmation Signals - baoquankhu1.vn
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Lowered by Wall Street Zen - MarketBeat
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data By Investing.com - Investing.com South Africa
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com Australia
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acrivon Therapeutics Inc Azioni (ACRV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Levy Adam D. | Chief Financial Officer |
Jan 14 '26 |
Buy |
1.70 |
8,832 |
14,999 |
20,983 |
| Devroe Eric | Chief Operating Officer |
Jan 13 '26 |
Buy |
1.72 |
10,000 |
17,218 |
75,308 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 30 '25 |
Sale |
1.41 |
437,881 |
617,412 |
3,403,025 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
May 01 '25 |
Sale |
1.34 |
298,886 |
400,507 |
3,104,139 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 25 '25 |
Sale |
1.95 |
1,054,669 |
2,056,605 |
4,306,189 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 29 '25 |
Sale |
1.41 |
250,000 |
352,500 |
3,840,906 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 28 '25 |
Sale |
1.56 |
215,283 |
335,841 |
4,090,906 |
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):